logo-loader
viewAnteris Technologies Ltd

Anteris Technologies changes name from Admedus Ltd following shareholder approval

Anteris is a structural heart company with technology, ADAPT® and DurAVR™, that solves critical issues with marketed heart valves.

Anteris Technologies Ltd - Anteris Technologies changes name from Admedus Ltd following shareholder approval
Anteris has offices in Australia, USA and Europe

Anteris Technologies Ltd (ASX:AVR) has changed its name from Admedus Ltd (ASX:AHZ) following shareholder approval at the company's annual general meeting this month.

Anteris is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients.

Its focus is on developing next-generation technologies with world-class partners.

Durable heart valve with ADAPT®

Competing in a potential US$8 billion market, the company is developing the world’s ‘most durable heart valve’ with its ADAPT® anti-calcification treatment platform technology.

ADAPT® has unique properties that are critical to longer-lasting aortic valves and has been used in more than 20,000 patients globally.

DurAVR™, built with ADAPT® technology, is a novel and highly durable 3D single-piece aortic valve for the treatment of aortic stenosis.

DurAVR™ also has unique properties that are critical to longer-lasting valves and is now in human clinical trials following successful preclinical studies.

Anti-calcification comparison

After successfully enrolling and discharging its first patient in a ‘first in human DurAVR™ SAVR Feasibility Clinical Study’ in April, the company has been progressing with preclinical animal studies.

A preclinical study is underway to compare anti-calcification properties of its proprietary ADAPT® treated tissue with other bovine and porcine tissues used in commercially available SAVR and TAVR valves.

Calcification plays a significant role in the failure of bioprosthetic and other tissue heart valve substitutes.

The study will be conducted in Minneapolis, USA, at a world-renowned preclinical facility with the aim being to evaluate anti-calcification properties in the established subcutaneous rat model.

Around 48 rats will be implanted and harvested implants will be processed for histological and calcium/phosphorus analysis initially at the end of four months.

Quick facts: Anteris Technologies Ltd

Price: 5.15 AUD

ASX:AVR
Market: ASX
Market Cap: $30.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

1 day, 4 hours ago

2 min read